Suppliers / Lantech Pharmaceuticals

Lantech Pharmaceuticals

India Updated 9 July 2026

Lantech Pharmaceuticals is an API manufacturer based in India. It holds one active US drug master file. Customs aggregates show $1K of exports covering 1 molecule to 1 destination in 2023.

1
active US DMFs
0
valid CEPs
0
registered plants
0
filings across 0 regulators

What they file, and where

Molecule Regulators Docs
Lamivudine US FDA 1

Also appears on these molecule pages

Lamivudine API

Scale

Year Revenue Exports Destinations
2023 Not reported $1K 1
2022 Not reported $388K 4

Export figures are customs aggregates. We do not publish the identity of any buyer.

Questions about Lantech Pharmaceuticals

Does Lantech Pharmaceuticals hold a US DMF or a CEP?
Lantech Pharmaceuticals holds 1 active US drug master file. A drug master file is a submission to the FDA describing how an ingredient is made; a CEP is the EDQM's certificate that the substance meets its European Pharmacopoeia monograph. Both are filings rather than approvals.
What does Lantech Pharmaceuticals make?
1 molecule is on record against Lantech Pharmaceuticals, including Lamivudine. Each links through to that molecule's full manufacturer list.

Answered from this company's own record. Where a register holds nothing, the question is not asked rather than answered with a zero. How we count our figures.

Comparing suppliers?

Choose your molecules and target markets. Lantech Pharmaceuticals comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Comparable suppliers

Apitoria Pharma shares 1 molecule Hetero shares 1 molecule Cipla shares 1 molecule Matrix Pharmacorp shares 1 molecule Lupin shares 1 molecule

Ranked by shared active ingredients where we have them, otherwise by country and comparable credentials.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability
Customs aggregates
Export values, molecule and destination counts